Central regions | Technology & innovation

Clinical trials for chronic B-type viral hepatitis get ‘green light’

25 Sep '12
Hepatera, a Russian biotech company set up in late 2011 to develop and commercialize drugs to fight liver disorders, has received approval by the Russian Ministry of Healthcare for Ib-IIa phase clinical trials of its new drug candidate, Myrcludex B, in patients with chronic B-type viral hepatitis, the official Russian Venture Company (RVC) website reports.

The start-up has received investment for this work from Maxwell Biotech, a Russian VC fund co-established by Russian Venture Company. RVC is the Russian fund of funds and one of this country’s so-called development institutions (alongside Rusnano, Skolkovo, VEB Bank and some others).

Hepatera reportedly pushes this Myrcludex B project in collaboration with MYR GmbH, a German biotech firm financed by one of Western Europe’s largest VC funds, High-Tech Gründerfonds.

Marchmont reported on the earlier stages of the project this past March.

Under plans, Hepatera will conduct the clinical trials at specialized clinical centers in Moscow, St. Petersburg, Chelyabinsk (Urals) and Samara (Lower Volga).

The B-type viral hepatitis incidence is high in the world; about two billion people are believed to be carriers of the virus, and as many as 350 million of those are chronic patients. An estimated 5% of those with chronic B-type viral hepatitis also have the D-type hepatitis virus. This sort of cross-infection causes much faster and sometimes irreversible liver injuries.

According to Pavel Bogomolov, the chief hepatologist of the Moscow Regional Ministry of Healthcare, “…about 1.1 million Russian citizens need yearly B- and D-type viral hepatitis therapies.”

Myrcludex B is said to be of peptide origin and works by blocking the B- and D-type hepatitis viruses’ penetration into healthy hepatocytes (liver cells). This gives the liver some ‘room’ to restore its tissue and prevents deterioration and possible complications like cirrhosis and hepatocellular carcinoma.

This approach gives the researchers hope that a limited therapy will be enough to cure the disease. Antiviral nucleotide/nucleoside analogs prescribed by physicians today typically presuppose recurrent lifelong therapies.
Publish in Twitter
Write to Facebook
Google Buzz
Write to LiveJournal
Show in MM
Share MK
Find Related Content


Tags: Maxwell Biotech (19) / RVC (171) / clinical trials (12) / chronic B type viral hepatitis (0) / Myrcludex B (0) / Hepatera (0) /

Latest News: Central regions
28 Feb '20 | Finance, business | Technology & innovation
27 Feb '20 | Finance, business
26 Feb '20 | Retail, FMCG | Finance, business

Feature stories

26 Feb '20
A Russian developer has come up with its own...
25 Dec '19
Scientists in Siberia have come up with their own...
8 Nov '19
For the first time in the history of Russian-African...
Search (News archive - 21807)
Marchmont News

Latest News

28 Feb '20
AFK Sistema, a diversified LSE-listed Russian holding...
26 Feb '20
Intelligence Retail, a Russian service to analyze...
20 Feb '20
“Many investors rightly reckon that Russian start-ups...

Most read stories from last week

26 Feb '20
A Russian developer has come up with its own...
26 Feb '20
Intelligence Retail, a Russian service to analyze...
28 Feb '20
AFK Sistema, a diversified LSE-listed Russian holding...